CytoGene Therapeutics was founded in 2024 with the goal of developing new therapies to improve patient care. We were founded to develop innovative approaches to islet cell transplantation to provide a potential cure to patients with Type 1 Diabetes.
We use the latest biotech tools and technologies to develop our products and therapies. Our state-of-the-art labs and facilities are equipped with the latest equipment and software, and our team of scientists and researchers are constantly exploring new ways to use biotech to improve healthcare outcomes.
At CytoGene Therapeutics, we are committed to ethical and responsible biotech research and development. We believe in putting patients first, and we are dedicated to developing products and therapies that are safe, effective, and accessible to all.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.